Real World Data on CAR T-Cell Recipients: Are We There Yet?
Drs. Marcelo Pasquini and Miguel-Angel Perales discuss the history and significance of the Center for International Blood and Marrow Transplant Research (CIBMTR), a decades
A New Standard Emerges: Rational Use of Venetoclax to Inhibit BCL-2 Allows Treatment of AML In Older Patients
Dr. DeZern discusses two studies that show improved outcomes for older patients with AML using a venetoclax and hypomethylating agents combination.
Dr. Taylor and Dr. Abdel-Wahab look back at studies from 2018 that show great progress in therapies for myelodysplastic syndromes.
Dr. Abdel-Wahab reviews a study that looks at the use of circulating tumor DNA measurements to predict early outcome in diffuse large B-cell lymphoma and calls for implementation of clinical trials.
Dr. Abdel-Wahab reviews a study that suggests dissemination of bacteria from the gastrointestinal system and ensuing microbial-dependent inflammation may drive the development of myeloid malignancy in subjects with clonal hematopoiesis.
Dr. Abdel-Wahab looks at several studies that show different ways to reactivate wild-type p53 as a therapeutic option in leukemia and other forms of cancer.
Dr. Abdel-Wahab looks at a study that evaluates the efficacy of PD-1 inhibition in myeloproliferative neoplasms, focusing on how JAK2 mutations affect PD-L1 expression.
Dr. Abdel-Wahab takes a look at studies that explore the enzyme METTL3 and RNA methyltransferases as a novel therapy for acute myeloid leukemia.
Dr. Abdel-Wahab reviews the FDA approval in 2017 of four new therapeutic options for treating acute myeloid leukemia patients.
Dr. Abdel-Wahab discusses the use of vitamin C to restore TET2 deficiency in combination with PARP inhibition in the treatment of leukemia.
Dr. Abdel-Wahab and Dr. Taylor look at a study that evaluates the safety of combining the anti-PD-L1 antibody atezolizumab with the novel hypomethylating agent guadecitabine in older adults with AML not eligible for standard induction therapy.
Dr. Abdel-Wahab provides an overview of histiocytoses or histiocytic neoplasms, some of the most challenging hematologic disorders to diagnose and categorize.
January-February 2019Volume 16, Issue 1
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology